In phase II studies Apatorsen improved outcomes in bladder, prostate cancers

UCLA radiation oncologists awarded $1.8M to advance personalized cancer therapy

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have received a $1.8 million grant from NCI to advance their work in personalizing cancer treatment.

July 12, 2024

Vol.50 No.28

Drugs & Targets

FDA grants Fast Track designation to 225Ac-FL-020 radiopharmaceutical for mCRPC

FDA granted Fast Track designation for Ac-FL-020, a radiopharmaceutical which targets prostate-specific membrane antigen for the treatment of metastatic castration-resistant prostate cancer.xxx:more

July 12, 2024

Vol.50 No.28

Clinical Roundup

AI improves physicians’ ability to identify prostate cancer extent

Investigators from UCLA Health found using artificial intelligence to help map out the boundaries of cancerous prostate tissue can significantly reduce the risk of underestimating the extent of prostate cancer—an advancement that can help ensure an accurate diagnosis, precise treatment planning and effective surgical procedures.

June 14, 2024

Vol.50 No.24

Clinical Roundup

AI-based biomarker stratifies metastasis risk in patients with BCR post-prostatectomy

ArteraAI has validated its first multimodal artificial intelligence digital pathology-based post-radical prostatectomy biomarker for stratifying risk of metastasis and identifying differential absolute benefit for the addition of hormone therapy to salvage radiation therapy in radical prostatectomy patients with biochemical recurrence.

May 10, 2024

Vol.50 No.19

Clinical Roundup

AI tool predicts success of focal therapy for prostate cancer

Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, unveiled the results of a new UCLA study examining the role of AI in identifying tumor margins and predicting the efficacy of focal therapy treatments.

May 10, 2024

Vol.50 No.19

Drugs & Targets

FDA approves Anktiva for non-muscle-invasive bladder cancer

FDA has approved ImmunityBio’s Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin for the treatment of patients with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors.

April 26, 2024

Vol.50 No.17

In phase II studies Apatorsen improved outcomes in bladder, prostate cancers

YOU MAY BE INTERESTED IN

UCLA radiation oncologists awarded $1.8M to advance personalized cancer therapy

FDA grants Fast Track designation to 225Ac-FL-020 radiopharmaceutical for mCRPC

AI improves physicians’ ability to identify prostate cancer extent

AI-based biomarker stratifies metastasis risk in patients with BCR post-prostatectomy

AI tool predicts success of focal therapy for prostate cancer

FDA approves Anktiva for non-muscle-invasive bladder cancer

Renew today!

Subscriber content

Login